


# WeeOverview



# Overview: Sunday, 02 Sep, 2018

	E-Poster Area E-Poster	Gold Hall Gold	Grand Hall 1/2 GH 1/2	Hall 300 H 300	Meeting Studio 211/212 MS 211/212	Meeting Studio 311 MS 311	Meeting Studio 312 MS 312	Meeting Studio 313 MS 313	Meeting Studio 314/316 MS 314/316	Meeting Studio 315 MS 315
07:00										
08:00										
09:00										
10:00										
11:00										
12:00										
13:00										
14:00				CEC3 – Application of non-animal (toxico)kinetic data and tools in risk assessment from basic research to practice						
15:00					EU-ToxRisk – EU-ToxRisk: status quo of the Horizon2020 flagship project on non-animal toxicology					
16:00										
17:00			EX – Exhibition							
18:00		Opening – Opening Ceremony								
19:00	LP1 – Late Posters		Welcome – Welcome Reception							
20:00										
21:00										
22:00										
				CEC4 – Organ-specific in vitro modelling: state-of-the-art						
										CEC6 – Creating quantitative Adverse Outcome Pathways (AOPs)

# Overview: Monday, 03 Sep, 2018

	Copper Hall Copper	E-Poster Area E-Poster	Gold Hall Gold	Grand Hall 1/2 GH 1/2	Hall 100 H 100	Hall 300 H 300	Meeting Studio 311 MS 311	Meeting Studio 312 MS 312	Meeting Studio 314 MS 314	Meeting Studio 316 MS 316	Silver Hall Silver	The Arc Arc
07:00												
08:00												
09:00			KN02 – Keynote Lecture: Masayuki Yamamoto – NRF2 and its future									
10:00		LP2 – Late Posters	Session 1 – Organs on a chip in toxicology - is the end of animal testing near? SOT-Debate – EUROTOX-SOT Debate: Brigitte Landsmann and Daniel Willeneuve – Adverse Outcome Pathways are the future for regulatory toxicology									
11:00	Session 2 – Ensuring validity of in vitro replacements: what is needed for regulatory decision making?			Symp I – Symposium Optimising drug discovery by investigative toxicology: scientific advancements and case studies I	SOC 1 – Short oral communications 1					Session 3 – Chemical-induced immunosuppression in the 21st century	Session 4 – Non-clinical pharmacology and toxicology assessment of monoclonal antibodies supporting human clinical trials	
12:00				PV 1 – Poster Viewing 1   Exhibition		IND 2 – Industry session by Wuxi AppTec						IND 1 – Industry Session by Cytosab
13:00												
14:00	Session 9 – Open Source Platforms in chemical risk assessment: Means to translate 21st century research and tools to the risk assessment community?		Session 8 – Systems-biology-based 3R methods in toxicology		Symp II – Symposium Optimising drug discovery by investigative toxicology: scientific advancements and case studies II	Session 5 – Oligonucleotides - do they warrant specific safety assessment?					Session 7 – Detecting immunotoxicity of nanomaterials: from in vitro to rapid predictive testing	Session 6 – Microphysiological human stem cell systems for toxicity testing
15:00												
16:00			Session 10 – Mechanism-based mitochondrial toxicity testing for chemical safety evaluation		Session 13 – Air pollution over and beyond the classical risk factors		IND 5 – Industry Session by Covance					
17:00	Session 11 – NRF2 and Inflammation										Session 12 – Old drugs in new guises: the toxicology of repurposing	
18:00												
19:00							SSM-1 – Carcinogenesis SS	SSM-2 – ERAS Risk Assessment SS	SSM-3 – ITCASS Immunotoxicology SS	SSM-4 – Molecular Toxicology SS		
20:00												
21:00												
22:00												

Overview: Tuesday, 04 Sep, 2018

	Copper Hall Copper	E-Poster Area E-Poster	Gold Hall Gold	Grand Hall 1/2 GH 1/2	Hall 100 H 100	Hall 300 H 300	Silver Hall Silver
07:00							
08:00							
09:00			K03 – Keynote Lecture: Bo Holmstedt Memorial Fund Lecture: N. J. Gooderham – Metabolism, inflammation and cancer				
10:00		LP3 – Late Posters		PV 2 – Poster Viewing 2   Exhibition			
11:00	Session 14 – Ecotoxicology and toxicology: bridging the gaps; Models and frameworks		Session 17 – Adverse Outcome Pathways and development of alternative methods		Session 15 – Developing safe medicines for children - non-clinical considerations	SOC 2 – Short oral communications 2	Session 16 – Innovative medicinal products - challenges for the safety assessment of adverse immune effects
12:00			SOTMAL – SOT Merit Award Lecture: Samuel M. Cohen – Cell proliferation and carcinogenesis: bad luck and the environment				
13:00							
14:00					IND 3 – Industry session by RTC S.p.a.		
15:00	Session 19 – Translational safety biomarkers: current and future trends		Session 18 – Ecotoxicology and toxicology: bridging the Gaps Contemporary challenges		Session 21 – New insights in the role of innate immunity in immunotoxicology	IND 4 – Industry session by Cosmetics Europe	Session 20 – Tools, trends, and technologies in modern CNS safety assessment: Mind your brain!
16:00							
17:00	Session 23 – Breeding IATAs for predicting DART by fusing high-dimensional data with biological knowledge		Session 22 – Mode of action as a key in risk assessment of chemical carcinogens		Session 24 – Cardiac Safety: Current state of the art		Session 25 – Developmental immunotoxicity
18:00							
19:00							
20:00							
21:00							
22:00							

Overview: Wednesday, 05 Sep, 2018

	E-Poster Area E-Poster	Gold Hall Gold	Hall 100 H 100	Hall 300 H 300	Silver Hall Silver
07:00					
08:00					
09:00		K04 – Keynote Lecture: Ruth A. Roberts – Drug discovery: if you want to see different results do things differently			
10:00	LP4 – Late Posters	Session 26 – Success of toxicology applications in society: from science to regulation and to implementation	Session 28 – Cytokine release assays: future directions	SOC 3 – Short oral communications 3	Session 27 – Integrating epidemiology and experimental toxicology to understand the risk of endocrine disrupting chemical mixtures on children
11:00					
12:00					
13:00		HESI CITE – HESI CITE Lecture Big data for biologists: Manasi Nandi – A maths in medicine case study			
14:00		CC-AP – Closing Ceremony and Awards presentation			
15:00					
16:00					
17:00					
18:00					
19:00					
20:00					
21:00					
22:00					